Float Short %

3.94

Margin Of Safety %

Put/Call OI Ratio

0.46

EPS Next Q Diff

0.49

EPS Last/This Y

2.71

EPS This/Next Y

2.44

Price

101.38

Target Price

159.65

Analyst Recom

1.44

Performance Q

-28.57

Relative Volume

1.28

Beta

0.3

Ticker: NBIX

22 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2025-03-20	NBIX	110.11	0.70	0.13	17893
2025-03-21	NBIX	112.28	0.69	0.02	18018
2025-03-24	NBIX	115.63	0.72	0.01	15024
2025-03-25	NBIX	116.2	0.71	0.05	15144
2025-03-26	NBIX	114.43	0.70	0.00	15203
2025-03-27	NBIX	113.98	0.70	0.00	15215
2025-03-28	NBIX	113.17	0.70	0.06	15223
2025-03-31	NBIX	110.77	0.69	8.00	15350
2025-04-01	NBIX	106.73	0.69	0.01	15367
2025-04-02	NBIX	108.26	0.68	0.02	15567
2025-04-03	NBIX	102.91	0.64	0.21	16147
2025-04-04	NBIX	96.03	0.52	0.27	15178
2025-04-07	NBIX	93.24	0.51	4.41	15526
2025-04-08	NBIX	87.61	0.37	3.03	14197
2025-04-09	NBIX	95.31	0.46	0.17	15307
2025-04-10	NBIX	90.64	0.46	1.00	15314
2025-04-11	NBIX	90.82	0.46	2.00	15310
2025-04-14	NBIX	94.53	0.46	5.25	15309
2025-04-15	NBIX	96.17	0.46	0.13	15312
2025-04-16	NBIX	100.17	0.46	0.09	15313
2025-04-17	NBIX	100.97	0.46	18.12	15431
2025-04-18	NBIX	101.38	0.46	18.12	15431
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

22 items 1 of 1

22 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-03-20	NBIX	110.07	12.9	30.4	6.36
2025-03-21	NBIX	111.92	12.9	43.4	6.36
2025-03-24	NBIX	115.60	12.9	53.8	6.36
2025-03-25	NBIX	116.18	12.9	35.3	6.36
2025-03-26	NBIX	114.45	12.9	21.7	6.36
2025-03-27	NBIX	113.94	10.3	28.9	6.32
2025-03-28	NBIX	113.16	10.3	26.9	6.32
2025-03-31	NBIX	110.60	10.3	16.4	6.32
2025-04-01	NBIX	107.00	10.3	10.0	6.32
2025-04-02	NBIX	108.31	10.3	40.3	6.32
2025-04-03	NBIX	102.88	10.3	-2.4	6.32
2025-04-04	NBIX	95.64	5.5	-16.4	6.21
2025-04-07	NBIX	93.29	3.8	14.8	6.20
2025-04-08	NBIX	87.54	3.8	-10.4	6.20
2025-04-09	NBIX	95.28	3.8	92.5	6.20
2025-04-10	NBIX	90.70	3.8	-1.3	6.20
2025-04-11	NBIX	90.81	3.8	33.1	6.20
2025-04-14	NBIX	94.89	3.8	62.5	6.19
2025-04-15	NBIX	96.16	2.0	41.1	6.19
2025-04-16	NBIX	100.12	1.0	60.2	6.19
2025-04-17	NBIX	101.38	-0.8	40.6	6.19
2025-04-18	NBIX	101.38	-0.8	31.9	6.11
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

22 items 1 of 1

22 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-03-20	NBIX	-8.65	2.11	3.33
2025-03-21	NBIX	-8.65	2.11	3.33
2025-03-24	NBIX	-8.65	2.20	3.33
2025-03-25	NBIX	-8.65	2.20	3.33
2025-03-26	NBIX	-8.65	2.20	3.40
2025-03-27	NBIX	-8.65	2.20	3.40
2025-03-28	NBIX	-8.65	2.20	3.40
2025-03-31	NBIX	-8.65	2.20	3.40
2025-04-01	NBIX	-8.65	2.20	3.40
2025-04-02	NBIX	-8.65	2.20	3.40
2025-04-03	NBIX	-8.65	2.20	3.40
2025-04-04	NBIX	-8.65	2.20	3.40
2025-04-07	NBIX	-8.65	2.48	3.40
2025-04-08	NBIX	-8.65	2.48	3.40
2025-04-09	NBIX	-8.65	2.48	3.40
2025-04-10	NBIX	-8.65	2.48	3.91
2025-04-11	NBIX	-8.65	2.48	3.91
2025-04-14	NBIX	-8.65	2.64	3.94
2025-04-15	NBIX	-8.65	2.64	3.94
2025-04-16	NBIX	-8.71	2.64	3.94
2025-04-17	NBIX	-8.71	2.64	3.94
2025-04-18	NBIX	-8.71	2.64	3.94
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

22 items 1 of 1

Last Quarter Act. EPS

Avg. EPS Est. Current Quarter

1.32

Avg. EPS Est. Next Quarter

1.49

Insider Transactions

-8.71

Institutional Transactions

2.64

Beta

0.3

Average Sales Estimate Current Quarter

598

Average Sales Estimate Next Quarter

646

Fair Value

105.73

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

35.8

Max Drawdown 5-Year %

-46.4

Target Price

159.65

P/E

30.81

Forward P/E

16.66

PEG

0.8

P/S

4.26

P/B

3.89

P/Free Cash Flow

EPS

3.29

Average EPS Est. Cur. Y

6.11

EPS Next Y. (Est.)

8.55

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

14.49

Relative Volume

1.28

Return on Equity vs Sector %

-6.8

Return on Equity vs Industry %

5.2

EPS 1 7Days Diff

-0.1

EPS 1 30Days Diff

-0.25

EBIT Estimation

31.9

Neurocrine Biosciences, Inc.

Sector: Healthcare

Industry: Drug Manufacturers - Specialty & Generic

Employees: 1800

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy and schizophrenia; NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, and NBI-1065890 for neuropsychiatric and neurological conditions. The company also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.

stock quote shares NBIX – Neurocrine Biosciences, Inc. Stock Price stock today

news today NBIX – Neurocrine Biosciences, Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch NBIX – Neurocrine Biosciences, Inc. yahoo finance google finance

stock history NBIX – Neurocrine Biosciences, Inc. invest stock market

stock prices NBIX premarket after hours

ticker NBIX fair value insiders trading

Investment involves risk. As a general rule, you should only trade in financial products that you are familiar with and understand the risk associated with them. The risk warning described in each financial product below is not exhaustive, you should carefully consider your investment experience, financial situation, investment objective, risk tolerance level and consult your independent financial adviser as to the suitability of your situation prior making any investment.

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: NBIX

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Get Started

About

Last Quarter Act. EPS

Average EPS Est. Cur. Y